FASN and metabolic dysfunction-associated steatotic liver disease: FASN (rate‐limiting enzyme in DNL) is believed to play key roles in NAFLD progression and development and HCC; therefore, inhibiting FASN may downregulate the DNL, decrease the accumulated fat within the cells, and decrease tumor growth.